“To Be or Not To Be,” Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity

Cappelli, Susanna; Randone, Silvia Bellando; Martinović, Dušanka; Tămaș, Maria Magdalena; Pasalic, K. Simic; Allanore, Yannick; Mosca, Marta; Talarico, Rosaria; Opriş, D.; Kiss, Csaba; Tausche, Anne Kathrin; Cardarelli, Silvia; Riccieri, Valeria; Koneva, O.; Cuomo, Giovanna; Becker, Mike; Sulli, Alberto; Guiducci, Serena; Radić, Mislav; Bombardieri, Stefano; Aringer, Martin; Cozzi, Franco; Valesini, Guido; Ananyeva, L. P.; Valentini, Gabriele; Riemekasten, Gabriela; Cutolo, Maurizio; Ionescu, Ruxandra; Czirják, László; Damjanov, Nemanja; Rednic, Simona; Cerinic, Marco Matucci

doi:10.1016/j.semarthrit.2011.07.010

Cited by 135 publications

(93 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patient cohort was already the subject of a previous study focusing on interstitial pneumonia with SSc-related autoantibody (15). SSc and MCTD were diagnosed when patients fulfilled the established criteria (19)(20)(21). Two patients developed manifestations of SSc during the follow-up period, and these patients were also included as SSc-ILD subjects.…”

Section: Study Samplementioning

confidence: 99%

Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease

Yamakawa¹,

Hagiwara²,

Kitamura³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Section: Study Samplementioning

confidence: 99%

Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease

Yamakawa¹,

Hagiwara²,

Kitamura³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

“…111 Similar to undifferentiated connective tissue disease, many patients with mixed connective tissue disease will, often years later, meet criteria for a specific RD. 112 Finally, patients who meet diagnostic criteria for more than one RD are described as having an overlap syndrome.…”

Section: Lung Involvement By Less-common Systemicmentioning

confidence: 99%

Pleuropulmonary Pathology in Patients With Rheumatic Disease

Schneider

Gruden

Tazelaar

et al. 2012

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Thoracic manifestations of rheumatic disease (RD) are increasingly recognized as a significant cause of morbidity and mortality worldwide. Rheumatologic underpinnings have been identified in a significant proportion of patients with interstitial lung disease. The 5 RDs most frequently associated with pleuropulmonary disease are (1) rheumatoid arthritis, (2) systemic lupus erythematosus, (3) progressive systemic sclerosis, (4) polymyositis/dermatomyositis, and (5) Sjögren syndrome. The onset of thoracic involvement in these diseases is variable. In some patients, it precedes the systemic disease or is its only manifestation. Moreover, there is a wide spectrum of clinical presentation ranging from subclinical abnormalities to acute respiratory failure. Histopathologically, the hallmark features of thoracic involvement by RD are inflammatory, targeting one or more lung compartments. The reactions range from acute to chronic, with remodeling by fibrosis being a common result. Although the inflammatory findings are often nonspecific, certain reactions or anatomic distributions may favor one RD over another, and occasionally, a distinctive histopathology may be present (eg, rheumatoid nodules). Three diagnostic dilemmas are encountered in patients with RD who develop diffuse lung disease: 1) opportunistic infection in the immunocompromised host, 2) drug toxicity related to the medications used to treat the systemic disease, and 3) manifestations of the patient's known systemic disease in lung and pleura. To confidently address the latter, the 5 major RDs are presented here, with their most common pleuropulmonary pathologic manifestations, accompanied by brief clinical and radiologic correlations.

show abstract

“…В исследовании S. Cappelli и соавт. [68] были от-мечены клинически значимые ассоциации U1-РНП аутоАТ с другими антиядерными антителами и клиническими про-явлениями: анти-Sm -с вовлечением почек, анти-SSA/Ro -с вовлечением нервной системы и легких, анти-Scl-70 -с поражением пищевода, АЦА-со склеродактилией, анти-dsDNA и анти-SSA/Ro -с серозитами.…”

unclassified

“…Так, некоторые авторы связывают позитивность по антите-лам к U1-РНП с перекрестным синдромом, при котором у больного имеется сочетание двух РЗ, удовлетворяющих двум классификационным критериям [68]. Наряду с кон-цепцией самостоятельного заболевания существует мнение о том, что СЗСТ -это дебют иной конкретной системной болезни.…”

unclassified

“…Длительные наблюдения показывают нередкую эволюцию СЗСТ в типичные формы ССД или СКВ [78,79]. В то же время около половины больных сохраняют стабиль-ную клинико-иммунологическую картину на протяжении многих лет [68,80,81]. В этом плане интересна гипотеза о протективности аутоАТ к U1-РНП, согласно которой их на-личие ассоциируется с более мягким и благоприятным тече-нием РЗ и медленным его прогрессированием [71].…”

unclassified

See 1 more Smart Citation

Positivity for antiribonucleoprotein antibodies in rheumatic diseases: focus on scleroderma systematica

Shayakhmetova¹,

Ananyeva²

2017

RJTAO

View full text Add to dashboard Cite

Обзор посвящен проблеме антителообразования при системной склеродермии (ССД), с акцентом на антитела к рибонуклеопроте-ину (РНП): частоте встречаемости, структуре, клиническим ассоциациям. ССД -прогрессирующее полисиндромное заболевание с характерным поражением кожи, опорно-двигательного аппарата, внутренних органов (сердца, легких, пищеварительного тракта, почек)

show abstract

“To Be or Not To Be,” Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity

Cited by 135 publications

References 32 publications

Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease

Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease

Pleuropulmonary Pathology in Patients With Rheumatic Disease

Positivity for antiribonucleoprotein antibodies in rheumatic diseases: focus on scleroderma systematica

Contact Info

Product

Resources

About